Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Ceapro Inc V.CZO

Ceapro Inc. is a Canada-based biotechnology company. The Company is involved in the development of extraction technology and the application of this technology to the production of extracts and active ingredients from oats and other renewable plant resources. Its primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human, and animal health industries using technology, natural, renewable resources, and developing products, technologies, and delivery systems. The Company's products include a commercial line of natural active ingredients, including beta glucan, avenanthramides (colloidal oat extract), oat powder, oat oil, oat peptides, and lupin peptides, a commercial line of natural anti-aging skincare products, utilizing active ingredients, including beta glucan and avenanthramides and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner.


TSXV:CZO - Post by User

Bullboard Posts
Comment by billy4325on May 23, 2019 7:06pm
59 Views
Post# 29769528

RE:RE:Total sales of $3,197,000 for the first quarter of 2019

RE:RE:Total sales of $3,197,000 for the first quarter of 2019 Quite amazing, this company used to have close to 70% gross margins. Now that the "state of the art" facility is done, gross margins down to 42%. So much for the supposed increase in margins after the new facility is ready. Looks like the opposite has happened. What is the company going to to if the revenue fluctuates back down? They're have a good-sized loss as it is now.
lscfa wrote: Gross margin down to 42.4%.....
whatsmyname0 wrote:
  • Compared to $2,270,000 for the comparative period in 2018; an increase of 41% over last year. Avenanthramides sales volumes increased by 31% for Q1 2019 vs Q1 2018.
That's a good sign, hopefully it continues. 
 




Bullboard Posts